The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
Ambev SA ADR
ABEV · the NYSE · USD · Market cap $42.7B · 39,000 employees
Ambev S.A., through its subsidiaries, engages in the production, distribution, and sale of beer, draft beer, soft drinks, malt and food, and other beverages in Brazil, Central America and Caribbean, Latin America South,…
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price2.76 USD at the 13 Nov 2026 close
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.67)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $2.38 to $3.56, base estimate $2.94 (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.67, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Ambev SA ADR holds its Distribution at $2.76. Elevated stress, defensive posture warranted, held for 13 days.
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 13 days |
| Price at the screen | $2.76 |
| Valuation | 14.58 trailing · 13.46 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.22 |
Five Screens, Shown in Full
Does not pass. Excluded industry: Beverages - Brewers
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Excluded industry: Beverages - Brewers | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Ambev does not clear the screen at the business-activity stage. It operates in alcohol, so the financial ratios are not the deciding factor here.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ABEV's ethical verdict changes
Today ABEV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades at roughly a 6% discount to our $2.94 fair value, narrow competitive moat, 3.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 6.1% discount to the base estimate.
Third-party analyst targets: 10 covering, consensus Hold. The average target sits +10% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $2.94, with a range of $2.38 to $3.56, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBrazil beer maker fails ethics test outright
Picture a Friday night in Sao Paulo where every bottle of beer moves through one dominant local brewer. Ambev sits at the centre of that trade yet we pass without hesitation because the business sits in an excluded industry. The ethical screen exists for exactly these cases.
Numbers show a narrow moat, 18 percent profit margins and 17 percent ROE at a forward multiple of 14.1 times. Revenue is flat and the shares trade below our own fair value. None of that matters once the screen has ruled the name out.
Currency swings in Latin America and modest volume growth remain real pressures even in a defensive category. The market rates the stock a hold with a three dollar target that leaves little upside. Analysis, not advice.
| Forward P/E | 13.5xexpensive even after accounting for its growth |
| Trailing P/E | 14.6xreasonably valued |
| EPS, trailing | 0.19 |
| EPS, forward | 0.21 |
| Revenue growth | +3.6%slow but positive growth |
| Profit margin | 17.7%healthy profit margins |
| Return on equity | 17.7%a solid return on shareholder capital |
| FCF yield | 49.31% |
| Dividend yield | 4.76% |
| Debt to equity | 2.97heavy leverage: higher risk if revenue softens |
| Current ratio | 1.06adequate liquidity, worth monitoring |
| Beta | 0.22barely tracks the market's swings |
| 52-week range | 2.28 - 3.45 |
| Moat | NARROW |
| Market cap | $42.7B |
| Employees | 39,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Brazil and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeABEV trades on the NYSE (the company is based in Brazil). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3. Insiders have been net sellers over the past quarter.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (10 analysts) rates it hold, with a mean price target of $3.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Ambev Q3 Earnings Call Highlights Yahoo Finance · 18d ago
- Ambev (ABEV) Q3 2026 Earnings Call Transcript Yahoo Finance · 18d ago
- Ambev: Q3 Earnings Snapshot Yahoo Finance · 19d ago
- Is Ambev (ABEV) Outperforming Other Consumer Staples Stocks This Year? Yahoo Finance · 20d ago
- What Ambev Holders Bought Into Yahoo Finance · 21d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Crippa Prado Carla Smith De Vasconcellos | See Remarks | S - Sale | 60,757 | $187,739 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $3.28 | -5.2% | · | $948 | -5.2% |
| 2 months | $3.19 | -2.5% | · | $975 | -2.5% |
| 3 months | $2.87 | +8.4% | · | $1,084 | +8.4% |
| 6 months | $2.50 | +24.4% | · | $1,244 | +24.4% |
| 1 year | $2.43 | +28.2% | $0.02 | $1,292 | +29.2% |
| 2 years | $1.98 | +57.2% | $0.18 | $1,661 | +66.1% |
| 3 years | $2.71 | +14.8% | $0.32 | $1,267 | +26.7% |
| 5 years | $2.98 | +4.3% | $0.58 | $1,237 | +23.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ABEV does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.